Pictured: AbbVie building and pill bottles/Taylor Tieden for BioSpace
AbbVie has so far defended its majority market share among biologics for rheumatoid arthritis despite the loss of exclusivity for its flagship drug Humira (adalimumab). But for the first time since Humira biosimilars appeared…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
